Today, June 16, Massachusetts stem cell biotechnology company Asymmetrex announces that it will begin offering free tissue stem cell counting on its company website. Scheduled for opening July 5, Independence Day weekend in the U.S., the company’s counting site will give academic scientists, stem cell medicine physicians, tissue stem cell suppliers, and drug companies a new independence to begin incorporating exact numbers for tissue stem cell fraction and dosage in their research, stem cell treatments, cell manufacturing, and drug evaluations.
The director of stem cell biotechnology company Asymmetrex, Dr. James L. Sherley, M.D., Ph.D., is betting that if the stem cell medicine and pharmaceutical industries have easier access to stem cell counting, they will soon make it a routine part of their practice. So, starting July 5 of this year, Independence Day weekend in the U.S., Asymmetrex is offering free tissue stem cell counting at its website.
Obtaining a free stem cell count will only require entry of simple total cell count data at the company’s website. Counting total cells is a widely used, common practice throughout academic cell science, industrial cell manufacturing, drug development, and clinical medicine. However, counting tissue stem cells is only possible with Asymmetrex’s AlphaSTEM Test™ software technology. Simple cell culture procedures will be provided at the free stem cell count site. By following the simple cell culture and total cell counting procedures, any basic cell culture lab can generate the data needed for Asymmetrex to deliver a tissue stem cell-specific count to them in short order.
Asymmetrex’s tissue stem cell counting technology is a recent development for the industry. So, presently, its value is not widely known. There are many examples where the need for tissue stem cell counting has been ignored for years, because previously there was no way to do it. Counting would improve the design and interpretation of tissue stem cell research. Counting tissue stem cells would allow better optimization of cell and tissue manufacturing processes. Counting would provide better quality control for produced and transported tissue stem cell products. Counting would provide crucial dosages for stem cell treatments and stem cell clinical trials. Counting cord blood stem cells would make leukemia treatments for children more reliable. Counting tissue stem cells would provide inexpensive, early identification of stem cell-toxic drug candidates that would fail later in expensive clinical trials.
The planned free stem cell counting site is a part of Asymmetrex’s campaign to increase academic and industry awareness of the need for tissue stem cell counting and its value. In an earlier podcast series on “Counting Stem Cells” featured on the international stem cell industry networking platform RegMedNet, Director Sherley discusses the benefits of Asymmetrex’s technology for stem cell research, stem cell medicine, tissue stem cell biomanufacturing, pharmaceutical development, and environmental health science. Sherley now expects that, “The new free tissue stem cell counting site will give members of our industry the freedom to rediscover, for themselves, the value of counting.”
Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dosage and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies, cell biomanufacturing, and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.